Table 3.
Incidence of solicited systemic adverse events per vaccine type per dose
| First dose | Second dose | Third dose | |||||||||||||||||
| 15 μg MSP3 | 30 μg MSP3 | Engerix B | 15 μg MSP3 | 30 μg MSP3 | Engerix B | 15 μg MSP3 | 30 μg MSP3 | Engerix B | |||||||||||
| N = 15 | N = 15 | N = 15 | N = 15 | N = 15 | N = 15 | N = 15 | N = 15 | N = 15 | |||||||||||
| Symptom | Intensity | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| Any | Overall | 6 | 40 | 6 | 40 | 5 | 53 | 1 | 6.7 | 0 | 0 | 2 | 13 | 0 | 0 | 1 | 6.7 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Related | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Fever | Overall | 2 | 13 | 2 | 13 | 2 | 13 | 1 | 6.7 | 0 | 0 | 2 | 13 | 0 | 0 | 1 | 6.7 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Related | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Irritability | Overall | 2 | 13 | 0 | 0 | 2 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Related | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Drowsiness | Overall | 1 | 6.7 | 1 | 6.7 | 1 | 6.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Related | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Loss of appetite | Overall | 5 | 33 | 5 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Related | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |